Patient characteristics
| Variable . | Value . |
|---|---|
| Median age at CLL diagnosis, y (range) | 70 (57-80) |
| Sex, n (%) | |
| Male | 67 (61) |
| Female | 37 (34) |
| Data missing | 5 (5) |
| Race/ethnicity, n (%) | |
| White, non-Hispanic | 98 (90) |
| Black, non-Hispanic | 3 (3) |
| Asian | 2 (2) |
| Pacific Islander | 1 (1) |
| Data missing | 5 (5) |
| IGHV mutational status,* n (%) | |
| Unmutated | 8 (7) |
| Mutated | 26 (24) |
| Unknown/missing | 75 (69) |
| No. of available annually collected prediagnostic serum samples (per patient), n (%) | |
| 1 or 2 | 31 (29) |
| 3 or 4 | 41 (37) |
| 5 or 6 | 37 (34) |
| Median latency between blood draw and CLL diagnosis, y (range) | |
| First prediagnostic blood draw | 4.5 (0.04-10.2) |
| Last prediagnostic blood draw | 1.8 (0.01-8.9) |
| Variable . | Value . |
|---|---|
| Median age at CLL diagnosis, y (range) | 70 (57-80) |
| Sex, n (%) | |
| Male | 67 (61) |
| Female | 37 (34) |
| Data missing | 5 (5) |
| Race/ethnicity, n (%) | |
| White, non-Hispanic | 98 (90) |
| Black, non-Hispanic | 3 (3) |
| Asian | 2 (2) |
| Pacific Islander | 1 (1) |
| Data missing | 5 (5) |
| IGHV mutational status,* n (%) | |
| Unmutated | 8 (7) |
| Mutated | 26 (24) |
| Unknown/missing | 75 (69) |
| No. of available annually collected prediagnostic serum samples (per patient), n (%) | |
| 1 or 2 | 31 (29) |
| 3 or 4 | 41 (37) |
| 5 or 6 | 37 (34) |
| Median latency between blood draw and CLL diagnosis, y (range) | |
| First prediagnostic blood draw | 4.5 (0.04-10.2) |
| Last prediagnostic blood draw | 1.8 (0.01-8.9) |
IGHV mutational status defined in monoclonal B cells detected before CLL diagnosis.3